Latest News for: fsgs
Edit
FSGS Market Analysis and Forecast 2024-2034: Clinical Trials, Epidemiology, Medications, and Leading Companies by DelveInsight
GetNews 24 Nov 2025
Focal Segmental Glomerulosclerosis (FSGS) market size across the 7MM was estimated at approximately USD 734 million in 2022, with forecasts indicating consistent expansion over the assessment period.
Edit
The Galveston Daily News
06 Nov 2025
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented ...
Edit
Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN ...
Nasdaq Globe Newswire 05 Nov 2025
PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies and ...
Edit
Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), ...
Nasdaq Globe Newswire 05 Nov 2025
These insights facilitate efficient trial assessment and competitive advantage in FSGS therapeutic developments.
Edit
Renalys Pharma Reaches Japan PMDA Agreement on Phase III Clinical Trials of Sparsentan for Focal Segmental Glomerulosclerosis (FSGS) and Alport Syndrome (AS)
PR Newswire 17 Oct 2025
RE-021) — one investigating the use of sparsentan in focal segmental glomerulosclerosis (FSGS) and the other in Alport syndrome (AS) in Japan ... (FSGS) ... About Focal Segmental Glomerulosclerosis (FSGS).
- 1